- Home
- JXJT vs MIRA Comparison
JXJT vs MIRA Comparison
Compare JXJT & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- MIRA
- Stock Information
- Founded
- JXJT 2012
- MIRA 2020
- Country
- JXJT China
- MIRA United States
- Employees
- JXJT N/A
- MIRA N/A
- Industry
- JXJT Apparel
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- JXJT Consumer Staples
- MIRA Health Care
- Exchange
- JXJT Nasdaq
- MIRA Nasdaq
- Market Cap
- JXJT 11.5M
- MIRA 17.1M
- IPO Year
- JXJT 2012
- MIRA 2023
- Fundamental
- Price
- JXJT $1.57
- MIRA $1.05
- Analyst Decision
- JXJT
- MIRA Strong Buy
- Analyst Count
- JXJT 0
- MIRA 2
- Target Price
- JXJT N/A
- MIRA $14.00
- AVG Volume (30 Days)
- JXJT 36.7K
- MIRA 552.1K
- Earning Date
- JXJT 11-01-2024
- MIRA 11-11-2024
- Dividend Yield
- JXJT N/A
- MIRA N/A
- EPS Growth
- JXJT N/A
- MIRA N/A
- EPS
- JXJT 0.48
- MIRA N/A
- Revenue
- JXJT $31,840,588.00
- MIRA N/A
- Revenue This Year
- JXJT N/A
- MIRA N/A
- Revenue Next Year
- JXJT N/A
- MIRA N/A
- P/E Ratio
- JXJT $3.40
- MIRA N/A
- Revenue Growth
- JXJT N/A
- MIRA N/A
- 52 Week Low
- JXJT $1.04
- MIRA $0.51
- 52 Week High
- JXJT $8.51
- MIRA $6.40
- Technical
- Relative Strength Index (RSI)
- JXJT 38.73
- MIRA 38.97
- Support Level
- JXJT $1.40
- MIRA $1.04
- Resistance Level
- JXJT $1.75
- MIRA $1.20
- Average True Range (ATR)
- JXJT 0.14
- MIRA 0.07
- MACD
- JXJT -0.04
- MIRA 0.02
- Stochastic Oscillator
- JXJT 32.08
- MIRA 19.44
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.